@Article{,
AUTHOR = {Daniel M. Bernad, Alan Dal Pra, Cintia Baule, 
Benicio N. Frey, Sergio Faria},
TITLE = {New-onset psychosis following androgen deprivation therapy for prostate cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {20},
YEAR = {2013},
NUMBER = {4},
PAGES = {6868--6870},
URL = {http://www.techscience.com/CJU/v20n4/61596},
ISSN = {1488-5581},
ABSTRACT = {Androgen deprivation therapy (ADT) is commonly used in the treatment of prostate cancer and is associated with several side effects including psychiatric disorders. We present an unusual case of a 62-year-old man with high risk prostate cancer that developed de novo psychosis after starting luteinizing hormone-releasing hormone (LHRH) agonists and discuss possible mechanisms to explain such fndings.  This case report highlights the importance of continuing assessment and monitoring of potential emotional and behavioral symptoms in prostate cancer patients treated with ADT.},
DOI = {}
}